These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

65 related articles for article (PubMed ID: 22710785)

  • 1. Economic analysis of epoetin alfa in critically ill trauma patients.
    Chui BK; Pannu N; Hazel M; Dong J; Tonelli M; Klarenbach SW
    J Trauma Acute Care Surg; 2012 Jul; 73(1):195-201. PubMed ID: 22710785
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Screening and prevention of venous thromboembolism in critically ill patients: a decision analysis and economic evaluation.
    Sud S; Mittmann N; Cook DJ; Geerts W; Chan B; Dodek P; Gould MK; Guyatt G; Arabi Y; Fowler RA; ;
    Am J Respir Crit Care Med; 2011 Dec; 184(11):1289-98. PubMed ID: 21868500
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The impact of methodological approach on cost findings in comparison of epoetin alfa with darbepoetin alfa.
    Song X; Long SR; Marder WD; Sullivan SD; Kallich J
    Ann Pharmacother; 2009 Jul; 43(7):1203-10. PubMed ID: 19584392
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Erythropoietic agents for anemia of critical illness.
    Shermock KM; Horn E; Rice TL
    Am J Health Syst Pharm; 2008 Mar; 65(6):540-6. PubMed ID: 18319499
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacokinetics and pharmacodynamics of once-weekly subcutaneous epoetin alfa in critically ill patients: results of a randomized, double-blind, placebo-controlled trial.
    Vincent JL; Spapen HD; Creteur J; Piagnerelli M; Hubloue I; Diltoer M; Roman A; Stevens E; Vercammen E; Beaver JS
    Crit Care Med; 2006 Jun; 34(6):1661-7. PubMed ID: 16607233
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Improved survival of critically ill trauma patients treated with recombinant human erythropoietin.
    Napolitano LM; Fabian TC; Kelly KM; Bailey JA; Block EF; Langholff W; Enny C; Corwin HL
    J Trauma; 2008 Aug; 65(2):285-97; discussion 297-9. PubMed ID: 18695463
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cost-effectiveness of recombinant human erythropoietin for reducing red blood cells transfusions in critically ill patients.
    MacLaren R; Sullivan PW
    Value Health; 2005; 8(2):105-16. PubMed ID: 15804319
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of darbepoetin alfa and epoetin alfa in the management of anemia of critical illness.
    Voils SA; Harpe SH; Brophy GM
    Pharmacotherapy; 2007 Apr; 27(4):535-41. PubMed ID: 17381380
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Economic analysis of decitabine versus best supportive care in the treatment of intermediate- and high-risk myelodysplastic syndromes from a US payer perspective.
    Pan F; Peng S; Fleurence R; Linnehan JE; Knopf K; Kim E
    Clin Ther; 2010 Dec; 32(14):2444-56. PubMed ID: 21353113
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A US multicenter, retrospective, observational study of erythropoiesis-stimulating agent utilization in anemic, critically ill patients admitted to the intensive care unit.
    Brophy GM; Sheehan V; Shapiro MJ; Lottenberg L; Scarlata D; Audhya P;
    Clin Ther; 2008 Dec; 30(12):2324-34. PubMed ID: 19167591
    [TBL] [Abstract][Full Text] [Related]  

  • 11. National cooperative rHu erythropoietin study in patients with chronic renal failure: a phase IV multicenter study. Report of National Cooperative rHu Erythropoietin Study Group.
    Nissenson AR
    Am J Kidney Dis; 1991 Oct; 18(4 Suppl 1):24-33. PubMed ID: 1928075
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cost-effectiveness analysis of degarelix for advanced hormone-dependent prostate cancer.
    Lu L; Peters J; Roome C; Stein K
    BJU Int; 2012 Apr; 109(8):1183-92. PubMed ID: 21883830
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cost-effectiveness of epoetin alfa therapy for anemia of end-stage renal disease.
    Moran LJ; Carey P; Johnson CA
    Am J Hosp Pharm; 1992 Jun; 49(6):1451-4. PubMed ID: 1529988
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The cost-effectiveness of treatment with erythropoietin compared to red blood cell transfusions for patients with chemotherapy induced anaemia: a Markov model.
    Borg S; Glenngård AH; Osterborg A; Persson U
    Acta Oncol; 2008; 47(6):1009-17. PubMed ID: 18770060
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The cost-effectiveness of Maze procedures using ablation techniques at the time of mitral valve surgery.
    Quenneville SP; Xie X; Brophy JM
    Int J Technol Assess Health Care; 2009 Oct; 25(4):485-96. PubMed ID: 19818194
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cost-effectiveness analysis of elective endovascular repair compared with open surgical repair of abdominal aortic aneurysms for patients at a high surgical risk: A 1-year patient-level analysis conducted in Ontario, Canada.
    Tarride JE; Blackhouse G; De Rose G; Novick T; Bowen JM; Hopkins R; O'Reilly D; Goeree R
    J Vasc Surg; 2008 Oct; 48(4):779-87. PubMed ID: 18639421
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Use and cost of erythropoiesis-stimulating agents in patients with cancer.
    Daniel G; Hurley D; Whyte JL; Willey V; Wilson M; Kallich J
    Curr Med Res Opin; 2009 Jul; 25(7):1775-84. PubMed ID: 19505205
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Epoetin alfa versus darbepoetin alfa in chemotherapy-related anemia.
    Cersosimo RJ; Jacobson DR
    Ann Pharmacother; 2006 Jan; 40(1):58-65; quiz 169-70. PubMed ID: 16332942
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A randomized, double-blind, placebo-controlled study to assess the effect of recombinant human erythropoietin on functional outcomes in anemic, critically ill, trauma subjects: the Long Term Trauma Outcomes Study.
    Luchette FA; Pasquale MD; Fabian TC; Langholff WK; Wolfson M
    Am J Surg; 2012 Apr; 203(4):508-16. PubMed ID: 22177550
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Use of epoetin alfa in critically ill patients.
    Pajoumand M; Erstad BL; Camamo JM
    Ann Pharmacother; 2004 Apr; 38(4):641-8. PubMed ID: 14966258
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.